Bcl-xL Cancer Research Results

Bcl-xL, Bcl-xL: Click to Expand ⟱
Source:
Type: pro-survival proteins
The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL.
BCL-XL overexpressing cells exhibited higher tumors sphere formation capacity and expressed higher levels of some stem cell markers, supporting the concept that BCL-XL plays essential roles in the maintenance of cancer stem cell phenotype.
PC, Pancreatic Cancer: Click to Expand ⟱
Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer.
Nanog is highly expressed in CSCs compared to normal cells [93–97]
HIF-1↑
Scientific Papers found: Click to Expand⟱
1537- Api,    Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
- Review, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
6184- Cuc,    Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells
- vitro+vivo, PC, NA
TumCG↓, TumCCA↑, Apoptosis↑, JAK2↓, STAT3↓, STAT5↓, P21↑, cycA1/CCNA1↓, CycB/CCNB1↓, Bcl-xL↓, ChemoSen↑, TumVol↓, toxicity↓,
6200- Cuc,  GEM,    Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer
- in-vivo, PC, NA
eff↑, TumCG↓, Bcl-xL↓, Bcl-2↓, cMyc↓, Casp↑, STAT3↓, JAK2↓,
881- RES,    Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, PANC1 - in-vitro, Pca, DU145
TumCCA↑, cycD1/CCND1↓, Bcl-xL↓, Mcl-1↓, other↓,
2353- TQ,    The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies
- Review, PC, NA
BioAv↝, BioAv↑, MUC4↓, PKM2↓, eff↑, TumVol↓, HDAC↓, NF-kB↓, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, COX2↓, PGE1↓,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 5,   BIM↑, 1,   Casp↑, 1,   Mcl-1↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Cell Cycle & Senescence ⓘ

cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   STAT3↓, 2,   STAT5↓, 1,   TumCG↓, 2,  

Migration ⓘ

MMPs↓, 1,   MUC4↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   JAK2↓, 2,   NF-kB↓, 1,   PGE1↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 2,   eff↑, 2,   Half-Life∅, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,   TumVol↓, 2,  
Total Targets: 40

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,  
Total Targets: 2

Scientific Paper Hit Count for: Bcl-xL, Bcl-xL
2 Cucurbitacin
1 Apigenin (mainly Parsley)
1 Gemcitabine (Gemzar)
1 Resveratrol
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:21  Cells:%  prod#:%  Target#:28  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page